Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Key Highlights
- ➤Tevogen signed non-binding LOI to evaluate potential HRK Healthcare acquisition
- ➤Potential transaction could expand Tevogen’s healthcare services infrastructure capabilities
- ➤Strategic initiatives could potentially support approximately $100 million in combined annual revenue
- ➤Transaction requires due diligence, definitive agreements, approvals, and customary closing conditions
Expert Statements
Manmohan Patel, MD and Tevogen lead investor
“I am pleased with Tevogen’s continued progress toward building an integrated healthcare enterprise.”
Manmohan Patel, MD and Tevogen lead investor
“The potential HRK transaction represents an opportunity to expand the Company’s healthcare services capabilities and advance its mission of improving the affordability and accessibility of life-saving medicines.”
Manmohan Patel, MD and Tevogen lead investor
“If consummated, this opportunity, together with other strategic acquisition initiatives, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue.”
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).
If consummated, the proposed transaction could expand Tevogen’s healthcare infrastructure capabilities and support the Company’s evolution into a revenue-generating healthcare enterprise comprised of Tevogen Bio, its biopharma arm; Tevogen.AI, its technology arm; and, subject to completion of proposed transactions, a healthcare services arm that may include management services.
Get started
Create a free account to read the full story.